SBIR/STTR Research Award

SBIR Phase I: Microfluidic 3D Bioprinting of Dacron-Recombinant Human Collagen Double-Network Crosslinked Biomimetic Vascular Conduits

Award identifier fe66c517b07ceb82e21b97d554219777ea1310efaacaf37cf91a901389b6a6a8Awarding agency National Science Foundation

Award amount

$304,906

Program and phase

SBIR · Phase I

Award year

2025

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
Linton Lifesciences
Proposal award date
2025-04-10
Contract end date
2026-03-31
UEI
JU2MKMVRZ4M3
Solicitation number
NSF 24-579
Topic code
BM

Research abstract

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project lies in the development of a next-generation vascular graft that improves outcomes for patients undergoing vascular surgeries. Vascular diseases are a leading cause of mortality worldwide, and there is a critical need for small-diameter vascular grafts that provide better durability, bioactivity, and mechanical compliance. Current graft options, including autologous vessels and synthetic alternatives, suffer from limitations such as poor long-term success rates, risk of blood clots, and mismatched mechanical properties that contribute to complications. This project addresses these challenges by developing a novel fabrication method that produces vascular grafts using a combination of synthetic and bioactive materials. The approach aims to enhance tissue integration, improve long-term performance, and reduce the need for repeat interventions. The potential commercial impact of this project is significant, as it aims to meet the growing demand for improved outcomes in both peripheral artery disease and coronary bypass procedures. Success in this work could lead to new medical solutions that lower healthcare costs, reduce patient complications, and provide a scalable alternative to current standards of care. This Small Business Innovation Research (SBIR) Phase I project focuses on developing an innovative bioprinting approach for creating vascular grafts that closely mimic the properties of natural blood vessels. The project seeks to overcome the limitations of current synthetic and biological grafts by utilizing a specialized bioprinting process that integrates a double-network hydrogel made from a Dacron synthetic polymer and recombinant human collagen. This combination allows for precise control over mechanical properties, including elasticity and compliance, while promoting cell adhesion and integration with native tissue. The research objectives include optimizing a custom bioprinting system for the Darcon blend, fine-tuning material compositions to achieve the desired mechanical properties, and evaluating the grafts for structural integrity and performance. The anticipated results include the successful production of vascular conduits with controlled dimensions, improved mechanical compatibility with native arteries, and enhanced biofunctionality for long-term graft success. If successful, this project will establish the foundation for a scalable, high-performance vascular graft technology that can address critical gaps in vascular and cardiovascular medicine. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

Technology keywords

Not reported

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.